Kjing34

Will the (approximately) 125 patient enrolled by your former CRO be evaluable to support the end result?

What "new information" was presented to Cel-Sci that made you remove your request to the FDA to enroll additional patients?

What exactly have you been lobbying the FDA for?

Will secondary endpoints be pursued if overall survival benefit isnt proven?

Will Cel-sci file for approval if a less than 10% improvement is shown?

Does Cel-sci reserve the right to pursue further litigation against its former CRO if the study does not succeed due to their mismanagement?